Aveo's Tivozanib kidney cancer drug will get the nod from regulators.
Five takeaways from Facebook’s Q1 earnings results
Facebook's mobile strategy is starting to deliver.
Patrick Larkin: Apple's buyback is perfectly timed
Tim Cook is a great capital strategist.
Gold: What happened?!
The inflation trade that went wrong.
Eric Steiman: Why I'm staying short Apple
The buyback was the only positive I could see in the report.
Charles Sizemore on CNBC: Apple looks like Microsoft 10 years ago
Multiple compression and a movement from growth to value hands.
Easy money should support global equities in 2013
The stock market may pause, but low interest rates will bolster equities.
Gallop along with the global nouveau riche
An investment theme worth considering.
Sell in May? Maybe not this year
The stock market has plenty of supports heading into the second half.
The Fed's liquidity party won't last forever
The day is approaching when the Fed will have to raise rates.